US court permits early launch of generic version of Teva MS drug

By REUTERS
July 26, 2013 20:55

WASHINGTON - Teva Pharmaceutical Industries' multiple sclerosis drug Copaxone will lose its patent protection in 2014 rather than 2015 because of a ruling from a US appeals court Friday.

The US Court of Appeals for the Federal Circuit issued its decision in a patent fight between Teva and rivals Sandoz and Mylan Inc.

The result is that a generic version of Copaxone can be launched in May 2014, a year early.


Related Content

Breaking news
April 23, 2018
Qatar denies its military planes intercepted UAE civilian aircraft

By REUTERS

Israel Weather
  • 14 - 25
    Beer Sheva
    14 - 22
    Tel Aviv - Yafo
  • 13 - 21
    Jerusalem
    14 - 22
    Haifa
  • 19 - 31
    Elat
    15 - 28
    Tiberias